Calliditas Therapeutics AB Announced That It Received A Notice Of Allowance From The United States Patent And Trademark Office For Patent Application No. 18/100,396 Entitled "New Pharmaceutical Compositions"
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics AB received a notice of allowance for a US patent application covering a method of treating IgA nephropathy with TARPEYO® (budesonide) delayed release capsules. The anticipated patent, expiring in 2043, will be the second US patent for TARPEYO and is expected to be Orange Book-listable. Calliditas plans to seek similar protections in other territories, including Europe and China, to strengthen TARPEYO's intellectual property and support the global NEFECON® franchise.
December 11, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calliditas Therapeutics is set to receive a new US patent for TARPEYO®, enhancing its IP protection and potentially its market exclusivity until 2043. This development could positively influence investor sentiment and the company's valuation in the short term.
The notice of allowance for a new patent typically has a positive impact on a biotech company's stock as it can protect the company's products from competition and secure revenue streams for a longer period. The anticipation of market exclusivity until 2043 for TARPEYO® should be viewed favorably by investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100